Trexquant Investment LP Trims Position in Harrow, Inc. $HROW

Key Points

• Trexquant Investment LP sold 84,853 shares of Harrow, Inc., reducing its holdings by 89.8% during the first quarter, leaving the firm with 9,647 shares valued at approximately $257,000.
• Several analysts have issued favorable ratings on Harrow's stock, with Cantor Fitzgerald setting a price target of $76.00, and the current consensus rating being "Buy" with a target price of $64.67.
• Harrow reported a quarterly EPS of $0.24, significantly surpassing analysts' estimates, although the company also faced challenges with revenue slightly below expectations.

Trexquant Investment LP decreased its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 89.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,647 shares of the company's stock after selling 84,853 shares during the period. Trexquant Investment LP's holdings in Harrow were worth $257,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of HROW. Two Sigma Investments LP grew its stake in shares of Harrow by 483.2% in the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company's stock worth $5,044,000 after acquiring an additional 124,574 shares in the last quarter. Nuveen LLC acquired a new position in shares of Harrow in the first quarter worth $2,046,000. Deutsche Bank AG grew its stake in shares of Harrow by 100.9% in the fourth quarter. Deutsche Bank AG now owns 108,064 shares of the company's stock worth $3,626,000 after acquiring an additional 54,273 shares in the last quarter. Royce & Associates LP grew its stake in shares of Harrow by 12.0% in the first quarter. Royce & Associates LP now owns 327,096 shares of the company's stock worth $8,701,000 after acquiring an additional 35,006 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Harrow by 89.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock worth $2,078,000 after acquiring an additional 29,262 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Performance

NASDAQ HROW traded up $3.40 during trading hours on Monday, hitting $42.82. The company had a trading volume of 1,290,439 shares, compared to its average volume of 442,589. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. Harrow, Inc. has a 1-year low of $20.85 and a 1-year high of $59.23. The company has a market cap of $1.58 billion, a PE ratio of -171.28 and a beta of 0.33. The business has a 50 day moving average of $36.35 and a 200-day moving average of $30.14.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

Wall Street Analysts Forecast Growth

HROW has been the subject of a number of analyst reports. William Blair initiated coverage on shares of Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating for the company. HC Wainwright boosted their target price on shares of Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 target price for the company. BTIG Research boosted their target price on shares of Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Finally, Zacks Research upgraded shares of Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $64.67.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.